MedCram lecture reviews IPF antifibrotic therapy, 2022 guideline update and AI drug claim

A MedCram lecture covers idiopathic pulmonary fibrosis, a chronic progressive fibrotic interstitial pneumonia of unknown cause, and its antifibrotic treatment and guideline updates. It reviews pirfenidone and nintedanib as disease-modifying drugs shown to slow progression in trials such as ASCEND and INPULSIS, and notes the 2022 clinical practice guideline update. The speaker also mentions rentosertib, described as an AI-generated candidate and the first AI drug to enter IPF phase 2, with a 71-patient phase 2A study, a claim the lecture itself flags as needing verification. Smoking cessation, avoiding harmful exposures and early treatment remain foundational.